ATE81153T1 - Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern. - Google Patents

Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.

Info

Publication number
ATE81153T1
ATE81153T1 AT90101351T AT90101351T ATE81153T1 AT E81153 T1 ATE81153 T1 AT E81153T1 AT 90101351 T AT90101351 T AT 90101351T AT 90101351 T AT90101351 T AT 90101351T AT E81153 T1 ATE81153 T1 AT E81153T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
expression system
production
variable region
constant region
Prior art date
Application number
AT90101351T
Other languages
English (en)
Inventor
Bradley Dr Zerler
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Application granted granted Critical
Publication of ATE81153T1 publication Critical patent/ATE81153T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT90101351T 1989-01-24 1990-01-24 Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern. ATE81153T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30121689A 1989-01-24 1989-01-24
US44170289A 1989-12-04 1989-12-04

Publications (1)

Publication Number Publication Date
ATE81153T1 true ATE81153T1 (de) 1992-10-15

Family

ID=26972226

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90101351T ATE81153T1 (de) 1989-01-24 1990-01-24 Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.

Country Status (12)

Country Link
EP (1) EP0380068B1 (de)
JP (1) JPH02295487A (de)
AT (1) ATE81153T1 (de)
AU (1) AU641907B2 (de)
CA (1) CA2008259A1 (de)
DE (1) DE69000338T2 (de)
DK (1) DK0380068T3 (de)
ES (1) ES2052077T3 (de)
FI (1) FI900332A7 (de)
IL (1) IL93118A0 (de)
NZ (1) NZ232201A (de)
PT (1) PT92900A (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362531B1 (de) 1988-09-01 1999-11-10 Bayer Corporation Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
EP0486526B2 (de) 1989-08-07 2001-03-07 Peptech Limited Bindeligande für tumornekrosisfaktor
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
ATE184049T1 (de) * 1990-07-20 1999-09-15 Bayer Ag Multimere formen des menschlichen rhinovirus- rezeptorproteins
GB2279077B (en) * 1990-12-21 1995-06-14 Celltech Ltd Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
DE07012626T1 (de) * 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
NZ269735A (en) * 1993-07-30 1998-01-26 Oravax Inc Monoclonal iga antibody against respiratory syncytial virus (rsv)
JP4731683B2 (ja) * 1997-08-22 2011-07-27 ユニバーシティ・オブ・グエルフ 卵中でのタンパク質の産生
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
FR3004184B1 (fr) 2013-02-26 2016-03-18 Agronomique Inst Nat Rech Anticorps anti-gluten desamide et utilisations.
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
EP3972690A4 (de) 2019-05-23 2023-07-05 Janssen Biotech, Inc. Verfahren zur behandlung einer entzündlichen darmerkrankung mit einer kombinationstherapie von antikörpern gegen il-23 und tnf-alpha
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
EP0256654B1 (de) * 1986-07-07 1996-09-18 Centocor, Inc. Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
KR900700134A (ko) * 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
ATE119198T1 (de) * 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.

Also Published As

Publication number Publication date
FI900332A0 (fi) 1990-01-22
EP0380068A1 (de) 1990-08-01
DK0380068T3 (da) 1992-11-02
NZ232201A (en) 1992-04-28
DE69000338D1 (de) 1992-11-05
PT92900A (pt) 1990-07-31
AU641907B2 (en) 1993-10-07
FI900332A7 (fi) 1990-01-22
IL93118A0 (en) 1990-11-05
DE69000338T2 (de) 1993-02-25
CA2008259A1 (en) 1990-07-24
JPH02295487A (ja) 1990-12-06
EP0380068B1 (de) 1992-09-30
AU4876690A (en) 1990-08-02
ES2052077T3 (es) 1994-07-01

Similar Documents

Publication Publication Date Title
DE69000338D1 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
ATE143052T1 (de) Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen
AU1042192A (en) Recombinant antibodies specific for a growth factor receptor
DE3382190D1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
EP0413763A4 (en) Method for the production of monoclonal antibodies utilizing a germfree animal
DE60039596D1 (de) Verfahren zur herstellung von monoklonalen antikörpern
EP0699755A3 (de) Verfahren zur Herstellung modifizierter Immunoglobulinen mit reduzierter Immunogenität der variablen Domänen einer murinen Antikörpers, Zusammensetzungen die diese enthalten
ATE263251T1 (de) Rekombinanter bakulovirus und sein verwendung zur herstellung monoklonaler antikörper
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
PT85995A (en) Process for preparing a chimeric antibody with specifity to human tumor antigen
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
DE3582358D1 (de) Monoklonaler antikoerper und verfahren zur quantitativen bestimmung von immunoglobulinen mittels dieses antikoerpers.
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
DE59209839D1 (de) Monoklonalantikörper, Linker- und Beta-Glucuronidase enthaltende Fusionsproteine zur Prodrug-Aktivierung, ihre Herstellung und Verwendung
DE59309133D1 (de) Granulozytenbindende Antikörperkonstrukte, ihre Herstellung und Verwendung
EP0287397A3 (en) Monoclonal antibody specific to human pancreatic phospholipase a2
JPS6463394A (en) Novel chimera polypeptide
AU625398B2 (en) Monoclonal antibody recognizing gamma atrial natriuretic polypeptide
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
EP0242154A3 (en) A novel tumor-associated antigen
DE3881101D1 (de) Monoklonal-antikoerper und methode fuer die bereitung von hybridoma, produzierend diese antikoerper.
EP0332421A3 (en) Monoclonal antibodies recognizing human psti, hybridomas producing the same, and their preparation and use
AU5790390A (en) A novel tumor associated antigen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee